Shares of Moderna Inc. (MRNA) took a significant hit in early trading on Monday, falling nearly 20% after the biotechnology company issued a downbeat revenue forecast for the upcoming years. With projections indicating a steep decline in revenue and an announcement of accelerated cost-cutting measures, investors responded with alarm, driving the stock to its lowest value since April 13, 2020.<\/p>\n
Moderna’s recent announcement revealed that it anticipates revenue to fall by approximately one-third in 2025, with expectations ranging between $1.5 billion to $2.5 billion. At the midpoint of this guidance, this reflects a staggering 34% drop when compared to existing estimates. Analysts at FactSet had previously projected revenues of about $2.92 billion, making Moderna’s guidance all the more concerning. The company’s stock plunged by 19.8% in afternoon trading, representing one of its most significant daily selloffs since going public in December 2018.<\/p>\n
For the year 2024, Moderna reported product sales between $3.0 billion to $3.1 billion, with the majority stemming from sales of its COVID-19 vaccine, Spikevax. Comparatively, revenues from the recently launched mResvia vaccine targeting respiratory syncytial virus (RSV) were nearly negligible. This performance falls short of earlier estimates, which projected sales could be between $3.0 billion and $3.5 billion.<\/p>\n
Moderna also indicated an aggressive approach to cost management, with planned savings of $1 billion this year followed by an additional $500 million in 2025. The company’s cash reserves are projected to dip significantly, from $9.5 billion at the end of 2024 to around $6 billion by 2025. This forecasted cash burn of more than $3 billion for the year highlights the financial pressures facing the company.<\/p>\n
Responding to the news, Evercore ISI analyst Cory Kasimov indicated a likely increase in investor skepticism regarding Moderna’s future performance, maintaining a ‘in line’ rating and setting a price target of $60. Such sentiments reflect a broader unease within the investor community concerning the company’s viability post-COVID-19, particularly as the pandemic\u2019s urgency fades.<\/p>\n
Adding to the company\u2019s tumultuous circumstances, the Data Safety Monitoring Board\u2014a committee of independent experts\u2014recently stated that a late-stage trial for Moderna’s cytomegalovirus (CMV) vaccine candidate did not meet necessary efficacy benchmarks, which is a setback for its product lineup. Amid these challenges, Moderna is actively pursuing approvals for its next-generation COVID-19 vaccine and a combined flu-COVID vaccine. In a positive development, after gaining approval for mResvia for seniors aged 60 and above, Moderna has simultaneously sought authorization for high-risk adults aged 18 to 59.<\/p>\n
The fall of Moderna shares is particularly striking when viewed in the context of overall market performance. Over the past year, Moderna’s stock has plummeted by an alarming 60.1%. During the same period, the iShares Biotechnology ETF (IBB) has dropped only 3.2%, while the S&P 500 index has displayed a robust 21.8% increase. This sharp divergence emphasizes the difficult road ahead for Moderna as it navigates post-pandemic challenges and seeks to redefine its role in biotechnology and vaccine development.<\/p>\n
In summary, Moderna’s stock decline to its lowest levels since the early days of the pandemic reflects deep investor concerns regarding future revenue streams and successful product commercialization. The acceleration of cost-cutting measures offers a glimpse of the company\u2019s strategy to adapt to the changing landscape, but with significant cash outflows expected and disappointing clinical results, the path forward appears fraught with uncertainty.<\/p>\n","protected":false},"excerpt":{"rendered":"
Moderna’s Stock Plummets to Post-COVID Lows Amid Disappointing Revenue Outlook Shares of Moderna Inc. (MRNA) took a significant hit in early trading on Monday, falling nearly 20% after the biotechnology company issued a downbeat revenue forecast for the upcoming years. With projections indicating a steep decline in revenue and an announcement of accelerated cost-cutting measures,…<\/p>\n","protected":false},"author":32,"featured_media":9608,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[685],"tags":[],"class_list":["post-9609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-stocks"],"_links":{"self":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/9609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/comments?post=9609"}],"version-history":[{"count":0,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/9609\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media\/9608"}],"wp:attachment":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media?parent=9609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/categories?post=9609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/tags?post=9609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}